Use and impact of intermittent versus continuous systemic treatment strategies in metastatic colorectal cancer in routine practice

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|121|16|2791-2798

ISSN： 0008-543x

Source： CANCER, Vol.121, Iss.16, 2015-08, pp. : 2791-2798

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Intermittent versus continuous erlotinib with concomitant modified “XELOX” (q3W) in first‐line treatment of metastatic colorectal cancer

By  

CANCER, Vol. 119, Iss. 23, 2013-12 ,pp. : 4145-4153

John Wiley & Sons Inc

Access to resources Recommend Favorite

Systemic Medical Treatment in Men with Metastatic Castration-Resistant Prostate Cancer: Recommendations for Daily Routine

By  

Oncology Research and Treatment, Vol. 38, Iss. 12, 2015-0 ,pp. : 654-668

Karger

Access to resources Recommend Favorite

Cost-Minimisation Analysis in First-Line Treatment of Metastatic Colorectal Cancer in France: XELOX versus FOLFOX-6

By  

Oncology, Vol. 79, Iss. 3-4, 2011-02 ,pp. : 174-180

Karger

Access to resources Recommend Favorite

Cancer survival in private and public

By  

INTERNAL MEDICINE JOURNAL, Vol. 45, Iss. 3, 2015-03 ,pp. : 267-274

John Wiley & Sons Inc

Access to resources Recommend Favorite

Variation in hospital treatment patterns for metastatic colorectal cancer

By  

CANCER, Vol. 121, Iss. 11, 2015-06 ,pp. : 1755-1761

John Wiley & Sons Inc

Access to resources Recommend Favorite